21.09.2025, 2220 Zeichen

AT&S: The Deputy CEO and EVP of the Business Unit Electronics Solutions, Peter Schneider, will step down from the Management Board of AT&S AG on September 30, 2025, in order to pursue new professional challenges. With the departure of Peter Schneider, CEO Michael Mertin will assume interim responsibility for the management of the Business Unit Electronics Solutions.
AT&S: weekly performance: 12.94%

AMAG: At its meeting on September 17, 2025, the Supervisory Board of AMAG Austria Metall AG resolved to extend the contract of Chief Sales Officer Victor Breguncci, MBA, until May 31, 2029. The Brazil native has been a member of AMAG’s Management Board since June 2019 and is responsible for Sales, Strategic Sales Development, Supply Chain Management, as well as Market Monitoring and Development. “In light of the current challenges facing the European aluminium industry, I am especially grateful for the trust placed in me. I look forward to continuing to take on responsibility together with my dedicated team and fellow board members. Our goal is to lead AMAG into the future as a reliable partner for high-quality aluminium solutions,” says Victor Breguncci. Since January 1, 2024, the AMAG Management Board has consisted of CEO and COO Dr. Helmut Kaufmann, CFO Claudia Trampitsch, and CSO Victor Breguncci, MBA.
Amag: weekly performance: -0.41%

Marinomed: Marinomed Biotech AG increased its sales revenue from €2.4 million to €7.2 million in the first half of the year. This includes initial payments of €5 million from the sale of the Carragelose business. Additional revenues came from the remaining Carragelose business, the service agreement with Unither, and Solv4U. Operating profit (EBIT) was EUR 21.0 million (H1 2024: EUR –3.2 million), significantly influenced by other operating income of EUR 19.3 million, which includes a restructuring gain of EUR 18.9 million. Cash flow from operating activities was slightly negative at EUR –0.2 million. Cash and cash equivalents as of June 30, 2025, amounted to EUR 1.5 million, compared to EUR 0.9 million in the previous year. 
Marinomed Biotech: weekly performance: -3.73%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (17/09/2025)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice: Sonderdividende oder Übergewinnsteuer, da nehmen wir zur Not allemal Marterbauers erste Wahl

Bildnachweis

Aktien auf dem Radar:FACC, VIG, Zumtobel, Austriacard Holdings AG, Pierer Mobility, Rosenbauer, Rosgix, Andritz, SBO, BKS Bank Stamm, Oberbank AG Stamm, Amag, Flughafen Wien, Österreichische Post, Polytec Group, Strabag, salesforce.com, Volkswagen Vz., Siemens, Fresenius Medical Care, HeidelbergCement, MTU Aero Engines, DAIMLER TRUCK HLD..., BMW, Deutsche Post, Porsche Automobil Holding, CPI Europe AG, AT&S.

---